Tesamorelin | GHRH Analogue Research Peptide
AUD $130
For laboratory research use only. Not for human use.
Research-grade Tesamorelin — a synthetic analogue of growth hormone-releasing hormone (GHRH) studied for visceral adiposity, body composition, and metabolic research. FDA-approved for HIV-associated lipodystrophy. Third-party HPLC tested. For laboratory research use only.
Supply Specifications
| Peptide | Tesamorelin (GHRH analogue, 44 amino acids) |
| Format | Lyophilised powder |
| Purity | ≥98% by HPLC |
| Testing | Third-party HPLC + Mass Spec |
| Storage | -20°C lyophilised |
| Use | Laboratory research use only |
| Price | AUD $130 |
Research Summary
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates pituitary growth hormone secretion. It received FDA approval (as Egrifta) for HIV-associated lipodystrophy — specifically for the reduction of excess abdominal fat in HIV-positive adults on antiretroviral therapy.
Preclinical and clinical research has examined Tesamorelin's apparent effects on visceral adiposity, body composition, and metabolic parameters. It is not TGA-approved in Australia and is available for laboratory research use only.
Related Research
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.